Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura

• Status: Terminated
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed. Giving photodynamic therapy during surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying the side effects and how well photodynamic therapy given during surgery works in treating patients with resectable non-small cell lung cancer that has spread to the pleura.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abramson Cancer Center of the University of Pennsylvania
• Collaborator: National Cancer Institute (NCI)
• Treatments: Dihematoporphyrin Ether; Trioxsalen

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed non-small cell lung cancer (NSCLC)

• Must have clinical and/or pathological evidence of pleural spread

• Primary tumor must be resectable as assessed by the attending thoracic surgeon

• Patients who have received or are currently receiving two-to-four courses of standard front-line chemotherapy are eligible

PATIENT CHARACTERISTICS:

• Must be medically fit to tolerate surgery

• No CTCAE v3.0 grade III-IV elevations in liver transaminases

• Bilirubin ≤ 1.5 mg/dL

• No known HIV infection

• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior treatment for NSCLC except pleurodesis or standard front-line chemotherapy

• No prior pemetrexed disodium chemotherapy

• No prior mantle radiotherapy

• No concurrent chemotherapy or radiotherapy during the active study treatment period

• Post-operative radiotherapy will be administered as clinically indicated